Loading evaluation data…
Preclinical evidence supports targeted therapeutic modulation of the NRF2/Keap1 pathway in the gastrointestinal tract, albeit human evidence is scarce.
therapeutic inference rests mainly on preclinical evidence with scarce IBD-specific human confirmation
Both natural and synthetic compounds as well as dietary components have shown to be of potential value in favorably affecting the NRF2/Keap1 axis
compound evidence is largely animal-based, mechanistically diverse, and clinically unvalidated in IBD
The NRF2/Keap1 pathway orchestrates cellular redox homeostasis and deregulation of this pathway is implicated in inflammatory bowel disease
mechanistic literature supports pathway involvement, while direct human IBD evidence remains limited and discordant
Derived from the full evaluation — not a separate score.
Strengths
The discussion reports that NRF2 activation can increase inflammation in acute colitis and that both deficiency and overactivation can worsen disease. It also describes bardoxolone-associated hypertension, proteinuria, glomerulosclerosis, and fibrosis.
↳ Dysregulation of the NRF2/Keap1 pathway; Current compounds
Table 1 compiles eight registered studies involving diets, broccoli sprouts, ginger, curcumin, resveratrol, and metformin, including status, design, sample size, and outcomes.
↳ Table 1
The conclusion explicitly states that human therapeutic evidence remains scarce and frames balanced NRF2 modulation as a challenge because both deficient and excessive activity may be harmful.
↳ Concluding remarks; Clinician’s Corner
Limitations
The article states that an extensive literature review was performed but gives no databases, search strategy, date range, screening process, or inclusion criteria. This prevents readers from assessing coverage and selection bias.
↳ Full article; author-contribution statement
The review overlaps with recent publications on oxidative stress, personalized redox medicine, and NRF2 in IBD, including References 4, 5, and 50. It does not clearly specify how its synthesis materially extends those accounts beyond organization and trial updating.
↳ Introduction; References 4, 5, and 50
The abstract says oxidative-stress trials produced mixed results, but the body mainly lists general limitations such as small cohorts and weak controls rather than examining the relevant IBD trials individually.
↳ Abstract; Current and upcoming compounds
The review's strongest feature is its coherent integration of pathway biology, candidate interventions, and an active clinical-trial inventory. Scores were constrained by the absence of a reproducible literature-selection method and by limited differentiation from recent related reviews. The article nevertheless handles major counterpoints directly, including the biphasic effects of NRF2 and bardoxolone-associated harms. Its therapeutic conclusions remain appropriately qualified, but translation is preliminary because most IBD-specific evidence is preclinical or comes from ongoing early-stage trials.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Sound3.1
The review organizes pathway biology, biomarkers, therapeutic mechanisms, nutrition, and an active-trial inventory into a useful reference. Its advance remains incremental because closely related prior reviews are cited without a clear account of what this synthesis uniquely adds.
“However, this is a simplistic definition based on mechanism of action.”
The argument proceeds coherently from pathway biology through biomarkers and compounds to clinical translation, while acknowledging hormesis and bardoxolone toxicity. No databases, search terms, date limits, or inclusion criteria explain how the literature was selected.
Sectioning, figures, and Table 1 make the broad synthesis followable, and central conclusions use calibrated terms such as “may,” “potential,” and “scarce.” The paratext is optimistic, but it also states the scarcity of human evidence and need for balanced modulation.
“However, human evidence supporting therapeutic interventions remains scarcely available.”
The review discusses the dual role of NRF2, discordant human tissue findings, and bardoxolone-related adverse effects rather than presenting the field as settled. Its motivating statement about mixed antioxidant-trial results is supported mainly through general design limitations rather than detailed trial-level analysis.
“Existing studies on antioxidant therapy in IBD often lack randomization or placebo control and involve small, varied cohorts.”
No concerns4 of 4 checks
The therapeutic argument consistently acknowledges that both NRF2 deficiency and overactivation can worsen colitis, and the conclusion retains that qualification. No numerical or claim-level internal contradictions were identified.
Funding and competing interests are disclosed, and ethics approval, data availability, and code availability are not required for this narrative review. No conduct concern was identified.
Flags: 1 declared / 5 total
99 of 100 checkable references verified
100 references in manuscript
No retraction notice found in Retraction Watch.
Sources: Retraction Watch ✓
Low2.8
The review addresses IBD clinicians, researchers, and trialists through concrete discussion of repurposed drugs, dietary compounds, and delivery systems. Their use in specific clinical decisions remains prospective rather than operational.
Most compound evidence is from animal models or human studies outside IBD, while the IBD trials listed are predominantly early-stage and ongoing. The findings therefore remain between mechanistic characterization and early proof of concept.
“The effectiveness for treating patients with IBD has yet to be demonstrated.”
The review spans diverse natural and synthetic compounds, but transfer across patients and disease states is constrained by heterogeneous models and the biphasic effects of NRF2 activity. The proposed personalized approach acknowledges rather than resolves this limitation.
“Both NRF2 deficiency and NRF2 activation increases the susceptibility to chemically induced colitis.”
The trial inventory and Outstanding Questions connect the synthesis to an active research pipeline involving biomarkers, safety, diet, and targeted delivery. This provides useful scaffolding for further research despite limited current clinical readiness.
AI-generated, human-governed. Something look off? Contact us to request a review.